Trials / Available
AvailableNCT03123029
Expanded Access to Venetoclax
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Venetoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Conditions
- Chronic Lymphocytic Leukemia (CLL)
- Multiple Myeloma
- Acute Myeloid Leukemia (AML)
- Non-Hodgkin's Lymphoma
- Acute Lymphoblastic Leukemia (ALL)
- Amyloidosis
- Plasma Cell Leukemia
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Venetoclax | Venetoclax will be administered orally. |
Timeline
- First posted
- 2017-04-21
- Last updated
- 2026-01-30
Source: ClinicalTrials.gov record NCT03123029. Inclusion in this directory is not an endorsement.